What is Pairwise?
Pairwise operates at the intersection of biotechnology and agriculture, leveraging CRISPR gene-editing to develop crops that are more adaptable to climate change and more convenient for consumer consumption. By focusing on the genetic optimization of plant traits, the company aims to replace resource-intensive supply chains with more efficient, sustainable, and plant-based alternatives. Their market position is defined by a commitment to precision agriculture, where genomic insights are translated into tangible improvements in crop yield and nutritional value, effectively bridging the gap between laboratory innovation and commercial-scale farming.
How much funding has Pairwise raised?
Pairwise has raised a total of $155M across 3 funding rounds:
Series A
$25M
Series B
$90M
Series C
$40M
Series A (2018): $25M with participation from Monsanto Growth Ventures and Deerfield Management
Series B (2021): $90M led by Deerfield Management, Temasek, Leaps by Bayer, and Pontifax AgTech Management
Series C (2024): $40M supported by Deerfield Management, Corteva Agriscience, and Aliment Capital
Key Investors in Pairwise
Deerfield Management
Deerfield Management is an investment firm focused on advancing healthcare through investment, intelligence, and philanthropy. The firm supports companies across the healthcare ecosystem with flexible funding models and drives innovation using AI, data, and market research.
Temasek
Founded in 1974, Temasek is a global investment company headquartered in Singapore. We are a generational investor, seeking to make a difference always with tomorrow in mind.
Aliment Capital
Aliment Capital is a pioneering growth capital investor in food and agriculture technology. The company invests globally in growing businesses that improve agricultural productivity, nutrition, health, sustainability and supply chain efficiency.
What's next for Pairwise?
With the successful closure of this latest capital round, Pairwise is expected to scale its operational capacity and expand its product pipeline. The strategic focus will likely shift toward commercializing its gene-edited crop varieties and deepening its partnerships within the global agricultural ecosystem. As the company moves into this next phase of development, the emphasis will remain on navigating regulatory landscapes and demonstrating the long-term economic and environmental benefits of its proprietary technology. The continued support from high-profile investors suggests a robust roadmap for market penetration and technological refinement in the coming years.
See full Pairwise company page
